SKK
CASC

Shepherd Kaplan Krochuk’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-20,000
Closed -$74K – 290
2017
Q4 		$74K Sell
20,000
-41,609
-68% -$170K 0.05% 222
2017
Q3 		$252K Buy
61,609
+3,500
+6% +$13.4K 0.21% 136
2017
Q2 		$216K Buy
58,109
+19,500
+51% +$77.4K 0.13% 160
2017
Q1 		$160K Buy
38,609
+12,048
+45% +$50.6K 0.08% 175
2016
Q4 		$114K Sell
26,561
-17,080
-39% -$110K 0.03% 214
2016
Q3 		$429K Hold
43,641
– – 0.09% 155
2016
Q2 		$247K Buy
+43,641
New +$296K 0.06% 216
2014
Q3 		– Sell
-3,417
Closed -$66K – 632
2014
Q2 		$66K Sell
3,417
-2,083
-38% -$36.7K 0.01% 534
2014
Q1 		$99K Buy
+5,500
New +$90.3K 0.01% 531

Shepherd Kaplan Krochuk's CASC Position: Q1 2018 in Review

Shepherd Kaplan Krochuk sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 20,000 shares — an estimated $74K sold.

Shepherd Kaplan Krochuk first reported a position in CASC in Q1 2014 and held it in 9 quarters. The position peaked at $429K in Q3 2016. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Shepherd Kaplan Krochuk reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 20,000 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $74K.
  • Shepherd Kaplan Krochuk first reported a position in Cascadian Therapeutics, Inc. in Q1 2014 and held it in 9 quarters.
  • Shepherd Kaplan Krochuk's Cascadian Therapeutics, Inc. position peaked at $429K in Q3 2016.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Shepherd Kaplan Krochuk's 13F filing for Q1 2018, filed 11 May 2018.